Publications by authors named "Ruwei Xing"

Claim this Profile
E
Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study.
Zhichao Liao, Jianjin Teng, Tao Li, Haotian Liu, Ting Li, Ruwei Xing

Front Immunol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumoral C2 Regulates the Tumor Microenvironment by Increasing the Ratio of M1/M2 Macrophages and Tertiary Lymphoid Structures to Improve Prognosis in Melanoma.
Gengpu Zhang, Shengnan Li, Wanyi Xiao, Chao Zhang, Ting Li, Ruwei Xing

Cancers (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic perspectives for adult soft tissue sarcoma-updates from the 2022 ASCO annual meeting.
Jilong Yang, Yu Xu, Yong Chen, Tao Li, Xiaowei Zhang, Ruwei Xing

Cancer Biol Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic features, prognostic factors, and outcomes of visceral sarcomas: A retrospective 12-year single-center study.
Songwei Yang, Zhichao Liao, Ting Li, Haotian Liu, Zhiwu Ren, Ruwei Xing

Front Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma.
Chao Zhang, Hongru Shen, Tielong Yang, Ting Li, Xinyue Liu, Ruwei Xing

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy Combined With Recombinant Human Endostatin (Endostar) Significantly Improves the Progression-Free Survival of Stage IV Soft Tissue Sarcomas.
Zhichao Liao, Chao Zhang, Tielong Yang, Haotian Liu, Songwei Yang, Ruwei Xing

Front Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacies and biomarker investigations of antiprogrammed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma.
Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Ruwei Xing

Cancer Biol Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Zhichao Liao, Ting Li, Chao Zhang, Xinyue Liu, Ruwei Xing

Cancer Biol Med· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
Xinyue Liu, Jin Xu, Feng Li, Zhichao Liao, Zhiwu Ren, Ruwei Xing

Biomed Pharmacother· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of surgery and/or combination chemotherapy for extraskeletal osteosarcoma: a single-center retrospective study from China.
Zhichao Liao, Minghan Qiu, Jilong Yang, Yun Yang, Lei Zhu, Peipei Xing, Ruwei Xing

Sci Rep· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety.
Zhichao Liao, Feng Li, Chao Zhang, Lei Zhu, Yehui Shi, Peipei Xing, Ruwei Xing

Exp Mol Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apatinib as targeted therapy for sarcoma.
Feng Li, Zhichao Liao, Chao Zhang, Jun Zhao, Ruwei Xing

Oncotarget· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.
Peipei Xing, Jin Zhang, Zhao Yan, Gang Zhao, Xubin Li, Ruwei Xing

Oncotarget· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis